8 completed, 6 terminated, 2 recruiting. 11 Phase 1, 6 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 5, Terminated 5, Recruiting 1 |
| Phase 2 | 6 | Completed 3, Recruiting 2, Terminated 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Molecular Partners AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors [212Pb]Pb-MP0712, [203Pb]Pb-MP0712 - Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) | Phase 1 / Phase 2 | Recruiting | Molecular Partners AG | 138 | 2026-05-18 | 2026-10-21 |
| MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma MP0317 + Gemcitabine + Cisplatine + Durvalumab, CT-Scan, Gemcitabine + Cisplatin + Durvalumab - Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Besancon | 75 | 2025-12-22 | 2026-06-01 |
| Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax - Leukemia, Myeloid | Phase 1 | Completed | Molecular Partners AG | 80 | 2022-12-29 | 2026-09-25 |
| First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen) - Advanced Malignant Solid Tumor | Phase 1 | Terminated | Molecular Partners AG | 46 | 2021-10-11 | 2025-01-30 |
| MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) MP0420, Placebo, Remdesivir - COVID-19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 485 | 2021-06-11 | 2024-02-05 |
| A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 ensovibep, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 407 | 2021-05-10 | 2026-01-27 |
| Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients ensovibep - Covid19 | Phase 2 | Completed | Molecular Partners AG | 12 | 2021-04-01 | 2021-09-08 |
| Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) Ensovibep, Placebo - COVID-19 | Phase 1 | Terminated | Molecular Partners AG | 53 | 2020-11-18 | 2022-03-18 |
| ACTIV-3: Therapeutics for Inpatients With COVID-19 LY3819253, Placebo, Remdesivir - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2753 | 2020-08-04 | 2023-08-25 |
| Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors MP0310 - Advanced Solid Tumor | Phase 1 | Completed | Molecular Partners AG | 38 | 2019-09-02 | 2022-12-22 |
| MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC MP0250 DARPin® drug candidate, Osimertinib - EGFR-mutated NSCLC (Disorder) | Phase 1 | Terminated | Molecular Partners AG | 8 | 2018-03-22 | 2023-03-23 |
| First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors MP0274 - Neoplasms | Phase 1 | Completed | Molecular Partners AG | 22 | 2017-08-08 | 2022-01-10 |
| A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma MP0250 plus BOR+DEX - Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Completed | Molecular Partners AG | 33 | 2017-05-23 | 2021-08-25 |
| First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients MP0250 - Neoplasms | Phase 1 / Phase 2 | Completed | Molecular Partners AG | 58 | 2014-07-01 | 2019-08-07 |
| Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration MP0112 - Wet Age-Related Macular Degeneration | Phase 1 | Terminated | Allergan | 32 | 2010-03-01 | 2014-05-12 |
| Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema MP0112 - Diabetic Macular Edema | Phase 1 | Terminated | Allergan | 18 | 2010-02-01 | 2014-05-13 |
COVID-19 (5) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Neoplasms (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Severe Acute Respiratory Syndrome (2) · Virus Diseases (2) · Carcinoma, Neuroendocrine (1) · Leukemia (1) · Small Cell Lung Carcinoma (1)
ensovibep (5) · MP0112 (2) · MP0250 (2) · remdesivir (2) · Azacitidine (1) · COVID-19 Drug Treatment (1) · Cisplatin (1) · Designed Ankyrin Repeat Proteins (1) · Gemcitabine (1) · bamlanivimab (1) · cilgavimab and tixagevimab drug combination (1) · durvalumab (1) · lufotrelvir (1) · osimertinib (1) · sotrovimab (1)
Switzerland (6) · United States (6) · France (5) · United Kingdom (5) · Netherlands (4) · Denmark (3) · Poland (3) · Spain (3) · Czechia (2) · Germany (2) · Greece (2) · Nigeria (2) · Singapore (2) · Uganda (2) · Austria (1)
James Neaton, Prof. (1) · Jens Lundgren, Prof. (1) · Prof. James Neaton (1) · Prof. Jens Lundgren (1)
PMID 35939810, PMID 24907435, PMID 33301375, PMID 33356051, PMID 34473343, PMID 34928698, PMID 34953520, PMID 35298440, PMID 35319751, PMID 35713300, PMID 35817072, PMID 37948759, PMID 38683145, PMID 39922466, PMID 40262279, PMID 42067655
2016 (2), 2014 (1), 2018 (1), 2023 (1)